FutuRx Portfolio

Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.

Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety. Bsense Bio’s approach is based on the targeting of two cation channels, a ligand-gated and a voltage-gated potassium channel, respectively, TRPV1 and […]

ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.

MabTrix is a preclinical stage biopharmaceutical company aiming to develop an innovative, function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) as the initial indication

Mitoconix Bio Ltd is pioneering a novel strategy to improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug.

SCIENTIFIC APPROACH NK cells play a major role in anti-cancer immunity. However, tumors may escape NK cell recognition by displaying various antigens that inhibit their activity. PiNK Biopharma is developing a novel immune checkpoint inhibitor against a protein expressed on cancer tissue, which acts as an inhibitory ligand for NK cells. Disrupting this interaction results […]

Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)

XoNovo is a biopharmaceutical company developing proprietary small molecules for the treatment of neurodegenerative diseases